Table 1 Summary of cancer drugs in this review
From: Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
Rapamycin analogues | Known target | Disease |
|---|---|---|
 Temsirolimus | mTOR | Renal cell carcinoma |
 Ridaforolimus (formerly known as Deforolimus) | mTOR | Breast cancer |
Soft tissue sarcoma | ||
Head and neck cancer | ||
Non-small cell lung cancer | ||
| Â | Â | Colorectal cancer |
 Everolimus | mTOR | Hormone receptor positive, HER2 negative breast cancer |
Inhibitors/Antibodies | Â | Â |
 Letrozole | Competitive inhibitor of aromatase | Breast cancer |
 Tamoxifen | Antagonist of estrogen receptor | Breast cancer |
 Trastuzumab | HER2 receptor | Breast cancer |
 Aromasin | Aromatase inhibitor | Hormone receptor positive, HER2 negative breast cancer |
 Lapatinib | EGFR | HER2 positive breast cancer |